Use of Incretin Agents and Risk of Acute and Chronic Pancreatitis: A Population-Based Cohort Study
January 2017. This population-based matched cohort study was conducted in a United Kingdom population to assess pancreatitis risk in patients with type 2 diabetes receiving incretin therapy (either dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists). Adult patients (N=182,428) using ≥1 diabetes medication (excluding insulin) were matched to controls without diabetes. Following adjustments for lifestyle, disease, and drug therapy, investigators found that current incretin therapy users had a 1.5-fold elevated risk for any pancreatitis and an approximately 2-fold elevated risk for acute pancreatitis compared to patients on non-incretin diabetes medications. No between-group difference was observed for risk of chronic pancreatitis.